Drug safety
HHS opens a legal path for six unapproved peptides. None of them are FDA-approved
By Kareem Brown
Published · Updated

The short answer: on October 30, 2026, the Department of Health and Human Services published a formal notice saying it does not plan to take enforcement action against licensed pharmacies, federal facilities or physicians who compound six specific peptides while the official compounding list is being written.
The six are BPC-157, TB-500, MOTS-c, Semax, epitalon and KPV - names that circulate widely in recovery, sleep and longevity communities. Until now they have mostly moved through a grey market of research-chemical sellers and wellness clinics.
This is not FDA approval. The policy is enforcement discretion: HHS is choosing not to act while rulemaking decides whether these peptides belong on the list of bulk substances pharmacies may legally compound.
What the policy actually allows
Only state-licensed pharmacies, federal facilities and licensed physicians qualify, and only while meeting ten conditions. No blends or stacks, no pre-filled injector pens, and ingredients must come from FDA-registered manufacturers.
Each batch must pass roughly twenty testing categories, with two independent methods confirming the peptide's identity, according to the conditions reported by BoxLife Magazine. Pharmacies offering oral BPC-157 must document that their specific formula is absorbed in humans.
The policy expires peptide by peptide as the FDA finishes its rules, and HHS can end it early if a safety signal or product quality issue appears. The Federal Register notice says plainly that it creates no rights and binds no one.
Why FDA staff argued against it
An FDA advisory committee voted narrowly in July to permit compounding of these six peptides. FDA staff scientists recommended the opposite, citing problems verifying the identity of the peptides and their salts, plus risks of impurities and microbial contamination, Clinical Observer reported.
The American Medical Association has called on HHS to withdraw the policy, Inside Health Policy reported on November 11. A public comment period on the docket closes November 13.
What the evidence actually says
None of the six is approved as a treatment anywhere, and human trial evidence is thin. Most of the familiar claims - faster tissue repair for BPC-157 and TB-500, metabolic effects for MOTS-c, cognition support for Semax - rest on animal or laboratory work, as Chemistry World noted.
Thin evidence cuts both ways. It is not proof of harm, and a regulated supply chain with mandatory identity and purity testing is very likely safer than anonymous vials ordered online, which was part of the stated reasoning behind the policy.
The open questions are real: whether compounded batches stay pure in practice, whether users combining several peptides create risks no single-peptide data can answer, and whether the FDA's final rules keep any of the six available at all.
What this means if you already use peptides
If the policy holds, the practical change is supply. Telehealth companies are already moving: Hims & Hers plans to offer some of the six, on pages that state the products are not FDA-approved and have not been assessed for safety, effectiveness or quality.
If you choose to use them, a licensed pharmacy with required testing is a meaningfully different product from a research-chemical website. That is a harm-reduction observation, not a recommendation: none of these peptides has proven benefits in humans, and none is risk-free.
Outside the US, nothing changed. The UK's medicines regulator has been seizing injectable peptides sold with health claims, and most regulators still treat these products as unlicensed medicines.
Sources (5)
- Federal Register notice: Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances (October 30, 2026)
- HHS enforcement discretion policy document (hhs.gov)
- Clinical Observer: HHS allows compounding pharmacies to sell six unapproved peptides (November 10, 2026, updated November 11)
- Inside Health Policy: AMA Calls On HHS To Rescind Peptide Access Policy (November 11, 2026)
- Morgan Lewis analysis: HHS Opens the Door to Compounding Certain Unapproved Peptides
This is news reporting and not medical advice.